Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001127855-13-000486
Filing Date
2013-07-15
Accepted
2013-07-15 16:07:12
Documents
10
Period of Report
2013-05-31

Document Format Files

Seq Description Document Type Size
1 NAPRODIS 10Q, 05.31.13 naprodis10q053113.htm 10-Q 351135
2 NAPRODIS 10Q, CERTIFICATION 302, CEO naprodisexh31_1.htm EX-31.1 10379
3 NAPRODIS 10Q, CERTIFICATION 302, CFO naprodisexh31_2.htm EX-31.2 10827
4 NAPRODIS 10Q, CERTIFICATION 906, CEO/CFO naprodisexh32.htm EX-32 6883
  Complete submission text file 0001127855-13-000486.txt   1979349

Data Files

Seq Description Document Type Size
5 napr-20130531_cal.xml EX-101.CAL 19183
6 napr-20130531_def.xml EX-101.DEF 7232
7 napr-20130531.xml EX-101.INS 194767
8 napr-20130531_lab.xml EX-101.LAB 64908
9 napr-20130531_pre.xml EX-101.PRE 53601
10 napr-20130531.xsd EX-101.SCH 9769
Mailing Address 13250 GREGG STREET SUITE F POWAY CA 92064
Business Address 13250 GREGG STREET SUITE F POWAY CA 92064 (858) 486-8655
Naprodis, Inc. (Filer) CIK: 0001313938 (see all company filings)

EIN.: 330903494 | State of Incorp.: NV | Fiscal Year End: 0831
Type: 10-Q | Act: 34 | File No.: 333-122009 | Film No.: 13968382
SIC: 2834 Pharmaceutical Preparations